Table 3

Association between ADPRT genotype and CaP risk

SubjectsGenotypeP value*VA versus VVAA versus VV
VVVAAACrude OR (95%CI)Adjusted OR (95% CI)Crude OR (95% CI)Adjusted OR (95% CI)
Caucasians
 Total controls31310771.00 (Ref.)1.00 (Ref.)1.00 (Ref.)1.00 (Ref.)
 Total cases306113190.021.08 (0.59–1.96)1.18 (0.85–1.64)2.78 (0.68–11.41)2.65 (1.08–6.49)
<65 years
 Controls1514821.00 (Ref.)1.00 (Ref.)1.00 (Ref.)1.00 (Ref.)
 Cases14441110.030.90 (0.36–2.23)1.11 (0.67–1.83)5.77 (0.58–57.51)§4.77 (1.01–22.44)
≥65 years
 Controls1625951.00 (Ref.)1.00 (Ref.)1.00 (Ref.)1.00 (Ref.)
 Cases1627280.491.22 (0.55–2.70)1.21 (0.78–1.87)1.60 (0.24–10.46)1.78 (0.55–5.82)
African Americans
 Total controls88901.00 (Ref.)1.00 (Ref.)
 Total cases45500.881.09 (0.14–8.28)0.98 (0.24–3.99)NANA
<65 years
 Controls6350
 Cases30300.93NANANANA
≥65 years
 Controls2540
 Cases15200.80NANANANA
  • * P value, Fisher’s exact or χ2 test.

  • OR adjusted for age, BPH, and FH.

  • Referent.

  • § An expected cell value is less than five; Fisher’s exact or χ2 test results should be considered.

  • Not applicable.